跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
RETEVMO - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
RETEVMO
Authorized
STANDARD
RETEVMO
loxo oncology inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
ae60feb63435d4f9
Company
loxo oncology inc
Type
Standard
Approval Details
Approval Id
ae60feb63435d4f9
Drug Approval Canada Name
RETEVMO
Product Name
RETEVMO
Status
Marketed
Status Date
2022-01-21
Original Market Date
2022-01-21
Din
02516918
Drug Class
Human
Dosage Form
Capsule
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EX22 SELPERCATINIB
Atc Name
l 01 ex 22
Aig Number
0162988001
Company Name
loxo oncology inc
Company Address
FL 9, 281 Tresser Blvd, Stamford, Connecticut, United States, 06901
Active Ingredients
SELPERCATINIB
40 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
ae60feb63435d4f9
Type
Standard
Back to Health Canada Approvals